SNGX
SOLIGENIX, INC.
Key Financials
Net Income
$-11080380
↓ 34.0%
Gross Profit
$97311
0.0%
Operating Income
$-11845476
↓ 25.5%
Revenue
$119371
0.0%
EPS (Diluted)
$-2.14
↑ 57.0%
Total Assets
$9.2M
↑ 3.0%
Total Liabilities
$3.9M
↓ 18.7%
Long-term Debt
$0.00
↓ 100.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/21/2026 | View on SEC |
| 4 | 9/18/2026 | View on SEC |
| 4 | 9/18/2026 | View on SEC |
| 4 | 9/18/2026 | View on SEC |
| 4 | 9/18/2026 | View on SEC |
| 424B3 | 8/7/2026 | View on SEC |
| 424B3 | 8/7/2026 | View on SEC |
| 424B3 | 8/7/2026 | View on SEC |
| 424B3 | 8/7/2026 | View on SEC |
| 10-Q | 8/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SNGX |
| Company Name | SOLIGENIX, INC. |
| CIK | 812796 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 609-538-8200 |